|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effect of anti-biofilm glass–ionomer cement on Streptococcus mutans biofilms显示文摘Dental restorative materials with antimicrobial properties can inhibit bacterial colonization, which may result in a reduction of caries at tooth-filling interaction zones. This study aimed to develop antibacterial glass–ionomer cements(GIC) containing a quaternary ammonium monomer(dimethylaminododecyl methacrylate, DMADDM), and to investigate their effect on material performance and antibacterial properties. Different mass fractions(0, 1.1% and 2.2%) of DMADDM were incorporated into the GIC. The flexure strength, surface charge density, surface roughness and fluoride release were tested. A Streptococcus mutans biofilm model was used. Exopolysaccharides(EPS) staining was used to analyze the inhibitory effect of DMADDM on the biofilm matrix. In addition, biofilm metabolic activity, lactic acid metabolism and the expression of glucosyltransferase genes gtf B, gtf C and gtf D were measured. GIC containing 1.1% and 2.2% DMADDM had flexural strengths matching those of the commercial control(P40.1). DMADDM was able to increase the surface charge density but reduced surface roughness(Po0.05). The incorporation of 1.1% and 2.2% DMADDM elevated the release of fluoride by the GIC in the first 2 days(Po0.05). The novel DMADDM-modified GIC significantly reduced biofilm metabolic activity(Po0.05) and decreased lactic acid production(Po0.05). The quantitative polymerase chain reaction(q PCR) results showed that the expression of gtf B, gtf C and gtf D decreased when mass fractions of DMADDM increased(Po0.05). EPS staining showed that both the bacteria and EPS in biofilm decreased in the DMADDM groups. The incorporation of DMADDM could modify the properties of GIC to influence the development of S. mutans biofilms. In this study, we investigated the interface properties of antibacterial materials for the first time. GIC containing DMADDM can improve material performance and antibacterial properties and may contribute to the better management of secondary caries. | Su-Ping Wang Yang Ge Xue-Dong Zhou Hockin HK Xu Michael D Weir Ke-Ke Zhang Hao-Hao Wang Matthias Hannig Stefan Rupf Qian Li Lei Cheng | 2016 | International Journal of Oral Science2016，8，2： | 5 |
| 2 | Nutritional status of gastric cancer patients after total gastrectomy 显示文摘 | Bae JM Park JW Yang HK | 1998 | World J Surg1998，22，3： | 2 |
| 3 | Adjuvant capecitabine and oxalipla- tin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial显示文摘 | Bang YJ Kim YW Yang HK | 2012 | Lancet2012，379，9813： | 1 |
| 4 | Anticoagulation Minimization ls Safe and Effective in Albumin Liver Dialysis Using the Molecular Ad sorbent Recirculating System显示文摘 | Tan HK Yang WS Chow P | 2007 | Artificial Organs2007，51，3： | 1 |
| 5 | Outcome after emergency surgery in gastric cancer patients with free perforation or severe bleeding显示文摘 | Lee HJ Park do J Yang HK | | 0，，04： | 1 |
| 6 | Ictal VEEG recording of three partial seizures in a patient with benign infantile convulsions associated with mild gastroenteritis显示文摘 | Imaik Otanik Yang HK | 1999 | Epilepsia1999，40，10： | 1 |
| 7 | Epstein-Barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with Epstein-Barr virus-negative carcinoma显示文摘 | Lee HS Chang MS Yang HK | 2004 | Clin Cancer Res2004，10，5： | 1 |
| 8 | Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC):a phase 3 open-label,randomised controlled trial显示文摘 | Bang Y J Kim YW Yang HK | | 0，，9813： | 1 |
| 9 | Expression of theinsulin-like growth factors (IGFs) and the IGF-binding proteins(IGFBPs) in human gastric cancer cells 显示文摘 | Yi HK Hwang PH Yang DH | 2001 | Eur J Cancer2001，37，： | 1 |
| 10 | Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label,randomised controlled trial显示文摘 | Bang YJ Kim YW Yang HK | 2012 | Lancet2012，379，9813： | 1 |
| 11 | Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC) :a phase 3 open-label, randomised controlled trial显示文摘 | Bang YJ Kim YW Yang HK | 2012 | Lancet2012，379，1： | 1 |
| 12 | Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC) : a phase 3 open - label, randomized controlled trial 显示文摘 | Bang Y J Kim YW Yang HK | 2012 | Lancet2012，379，9813： | 1 |
| 13 | An evolu -tionary algorithm for large traveling salesman problems 显示文摘 | TSAI HK YANG JM TSAI YF | 2004 | IEEE Transactions on Systems Man and Cybernetics Part B: Cybernetics (S1083- 4419)2004，34，4： | 1 |
| 14 | Laparoscopic gastrectomy for gastric cancer显示文摘 | Lee HJ Yang HK | 2013 | Dig Surg2013，30，2： | 1 |
| 15 | Evaluation of cortical perfusionin renal transplants:application of quantified power doppler ultrasonography显示文摘 | Wang HK Chou YH Yang AH | | 0，，07： | 1 |
| 16 | Serum uric acid concentration is associated with worsening in severity of diabetic retinopathy among type 2 diabetic patients in Taiwan-a 3-year prospective study显示文摘 | Lee J J Yang IH Kuo HK | 2014 | Diabetes Res Clin Pract2014，106，2： | 1 |
| 17 | Outcome after emer- gency surgery in gastric cancer patients with free perfo- ration or severe bleeding显示文摘 | Lee HJ Park do J Yang HK | 2006 | Dig Surg2006，23，4： | 1 |
| 18 | 胃切除术联合化疗与单纯化疗在具有一种单一不可治愈因素的进展期胃癌患者中的疗效对比研究(REGATTA):一项Ⅲ期随机对照研究显示文摘【摘要】背景和目的化疗是不可治愈进展期胃癌的标准治疗方案。对于具有一个单一不可治愈因素的进展期胃癌患者,姑息性胃切除术后加化疗能否提高此类患者的生存尚存争议。本研究目的是探讨姑息性胃切除术后化疗能否比单纯化疗在提高此类患者总体生存上更有优势。方法本研究是一项多中心、开放、随机、对照、Ⅲ期临床研究,包括日本、韩国、新加坡44个研究中心。患者是年龄20~75岁的具有一个单一不可治愈因素的进展期胃癌患者,这些不可治愈因素包括有局限于肝(H1)、腹膜(P1)、或腹主动脉旁淋巴结(16a1/b2)的转移。 | Fujitani K Yang HK Mizusawa J 戴伟钢 蔡世荣 | 2016 | 消化肿瘤杂志(电子版)2016，8，3： | 1 |
| 19 | Efficacy of recombinant human follicle-stimulating hormone in improving ooeyte quality in assisted reproductive techniques显示文摘 | Cheon KW Byun HK Yang KM | 2004 | J Reprod Med2004，49，9： | 1 |
| 20 | Nutritional stares of gastric cancer patients after total gastrectomy显示文摘 | Bae JM Park JW Yang HK | 1998 | World J Surg1998，22，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员